Comparative Study of Terbinafine Creams (Lamisil and EU 2000) in the Treatment of Tinea Corporis/cruris

Abstract

Objectiv e: To compare the efficacy of terbinafine creams (Lamisil ® and EU 2000®) in the treatment of tinea corporis/cruris.

Method: The study was designed as a prospective, comparative, randomized, parallel-group and double­ blind study. Out-patients of the Dermatology Clinic, Maharaj Nakom Chiang Mai Hospital, aged between 17-59 years, with a clinical diagnosis of tinea corporis/cruris confirmed by positive microscopy and culture were randomized to receive treatment once daily for I week with I% terbinafine cream, either Lamisil® or EU 2000® Patients were assessed at week 0, I, 2, 4 and 8. At each visit, signs and symptoms of erythema (redness), scaling, papulation. vesiculation and pruritus were scored and skin scrapings were taken for mycological examination.

Results: Thirty patients were included in the study, i.e. 16 treated with LamisiI® and 14 with EU 2000®. Demographic data showed that patients in the two treatment groups were comparable  with  regard  to  previous therapy, age, duration of disease, size and location of lesi ons. The causative organism was Trichophyton  rubrum in all patients. More than 50% efficacy in week 2 and the highest efficacy (about 90%) in week 4 were seen in both the Lamisil® and EU 2000® group. There was no difference in overall efficacy between the two groups (p>0.05) a·teach visit week .

Conclusion: Efficacy of EU 2000® cream in I week ' s treatment of tinea corporis/cruris is no different from that of Lam1s1l cream.